About the Company
A globally recognized non-profit professional medical society, this organization serves over 68,000 international members across 40 chapters, connecting cardiologists, advanced practice providers, and cardiovascular care teams worldwide. Headquartered in Washington, D.C. and founded in 1949, its mandate is to improve cardiovascular health globally through clinical practice guidelines, professional medical education, research publications, national registries, and hospital accreditation. Its learning programs are a trusted, evidence-based resource for healthcare professionals managing complex cardiac conditions.
Business Challenges
Despite compelling clinical trial data supporting the use of SGLT2 inhibitors in heart failure treatment, adoption among healthcare professionals remained critically low, with only 5.5% of eligible patients receiving the therapy. The barriers were not informational; they were structural and behavioral, requiring an education strategy designed to change how clinicians think and act in practice.
Key challenges included:
- Clinical Inertia at Scale: Clinicians were failing to initiate or intensify therapy even when treatment goals were unmet, a well-recognized barrier to improving outcomes across complex conditions.
- A Steep Learning Curve: Heart failure spans multiple phenotypes, comorbidities, and patient populations, requiring practical education on patient selection, dosing, contraindications, and monitoring, not just drug class awareness.
- Fragmented Reach: The target audience spanned cardiologists, heart failure specialists, advanced practice providers, pharmacists, and care teams across geographies and roles, with varying levels of familiarity with emerging evidence.
- The Pace of Guideline Adoption: Clinical guidelines can take up to 15 years to be fully adopted into practice. The organization needed a learning strategy capable of meaningfully compressing that timeline.
